Synthesis of Carboalkoxychloro- and Bromodiazirines
摘要:
The first known 3H-diazirines bearing a carbonyl group and a halogen atom on C-3 have been prepared by a novel synthetic method. Carboalkoxychloro- and bromodiazirines 1a-d are formed in up to 45% yields by reductive dechlorination of carboalkoxy-N,N,N'-trichloroformamidines 9a,b using chloride or bromide ion. This method constitutes the first example of the use of N,N,N'-trichloroamidines as starting materials in organic synthesis.
[EN] NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROARYLE-TRIAZOLE UTILISÉS COMME PESTICIDES
申请人:BAYER AG
公开号:WO2021069567A1
公开(公告)日:2021-04-15
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.
Design, Synthesis, and Conformational Analysis of Trispyrimidonamides as α-Helix Mimetics
作者:Lukas Spanier、Emanuele Ciglia、Finn K. Hansen、Krystina Kuna、Walter Frank、Holger Gohlke、Thomas Kurz
DOI:10.1021/jo402353z
日期:2014.2.21
The straightforward synthesis of trispyrimidonamides as a new class of α-helix mimetics is reported. Because of the versatility of our synthetic protocol, a variety of side chains including aliphatic, basic, aromatic, and heteroaromatic residues were included. A comprehensive conformational analysis revealed that in polar solvents a trimeric compound adopts conformations that can lead to i, i + 4,
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
申请人:Shanghai Hansoh Biomedical Co., Ltd.
公开号:EP3978490A1
公开(公告)日:2022-04-06
Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. In particular, disclosed are a compound as represented by general formula (I), a preparation method for the compound and a pharmaceutical composition containing the compound, and the use thereof as a KRAS G12C mutation inhibitor in treatment of diseases or symptoms such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer, wherein the definitions of substituents in general formula (I) are the same as those in the description.
WIELAND T.; SEELIGER A., J. LIEBIGS ANN. CHEM. <JLAC-BF>, 1976, NO 5, 820-823
作者:WIELAND T.、 SEELIGER A.
DOI:——
日期:——
Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy
作者:Maria Chatzopoulou、Daniel Conole、Enrico Emer、Jessica A. Rowley、Nicky J. Willis、Sarah E. Squire、Becky Gill、Steve Brough、Francis X. Wilson、Graham M. Wynne、Stephen G. Davies、Kay E. Davies、Angela J. Russell